Bristol Myers Squibb and Johnson & Johnson to discontinue phase 3 Librexia ACS trial of milvexian treat acute coronary syndrome: Princeton, New Jersey Monday, November 17, 2025, 1 ...
“Endotyping-informed therapy in the MRI-guided intervention arm led to a reduction in angina burden and an improvement in health-related quality of life,” reported the principal investigator Colin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback